Pear Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019
Revenue	12.69	4.21	9.38	32.56
Revenue Growth (YoY)	201.66%	-55.16%	-71.18%	-
Cost of Revenue	8.18	5.23	1.72	1
Gross Profit	4.51	-1.03	7.67	31.56
Selling, General & Admin	79.55	67.62	56.23	27.47
Research & Development	48.31	37.04	28.08	35.7
Operating Expenses	127.86	104.66	84.31	63.17
Operating Income	-123.35	-105.69	-76.64	-31.6
Interest Expense / Income	3.89	4.14	1.77	-1.42
Other Expense / Income	-51.75	-44.69	18.61	-20.85
Pretax Income	-75.49	-65.14	-97.02	-9.33
Net Income	-75.49	-65.14	-97.02	-9.33
Preferred Dividends	0	0	11.05	0
Net Income Common	-75.49	-65.14	-108.08	-9.33
Shares Outstanding (Basic)	139	113	89	15
Shares Outstanding (Diluted)	139	113	89	15
Shares Change	22.39%	27.03%	504.42%	-
EPS (Basic)	-0.54	-0.57	-1.21	-0.63
EPS (Diluted)	-0.54	-0.57	-1.21	-0.63
Free Cash Flow	-117.37	-112.32	-71.79	-36.88
Free Cash Flow Per Share	-0.85	-0.99	-0.81	-2.50
Gross Margin	35.54%	-24.36%	81.69%	96.94%
Operating Margin	-971.72%	-2511.53%	-816.75%	-97.05%
Profit Margin	-594.70%	-1548.05%	-1151.71%	-28.67%
Free Cash Flow Margin	-924.57%	-2669.23%	-765.07%	-113.25%
EBITDA	-65.9	-58.75	-94.83	-10.54
EBITDA Margin	-519.12%	-1396.06%	-1010.50%	-32.37%
Depreciation & Amortization	5.7	2.25	0.43	0.21
EBIT	-71.6	-61	-95.26	-10.75
EBIT Margin	-564.04%	-1449.57%	-1015.09%	-33.01%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).